Why it Matters

The American Gastroenterological Association continues its robust in-house lobbying strategy with $80,000 spent in Q1 2025. This represents a sustained commitment to direct advocacy rather than outsourcing to external firms. AGA has now reported over $6.1 million in total lobbying expenditures since 2003, demonstrating long-term strategic investment in policy influence.

By the Numbers

  • Q1 2025 Spending: $80,000 in internal lobbying costs
  • Historical Pattern: 77 disclosures totaling $6.12 million since 2003
  • External Support: Limited use of firms like Hart Health Strategies ($3.88M) for regulatory monitoring
  • Top Issues: Medical research (75 mentions), Medicare/Medicaid (73 mentions), health issues (61 mentions)

Broader Context

Gastroenterologists face mounting financial pressures from Medicare payment cuts and administrative burdens. Prior authorization delays increasingly impact colonoscopy scheduling and IBD treatments. NIH funding threats endanger digestive disease research programs. The March 2025 telehealth extension deadline creates policy urgency.

The Agenda

AGA targets five priority areas: reducing prior authorization burdens, securing fair Medicare reimbursement, eliminating step therapy delays, maintaining telehealth coverage, and preventing non-medical switching. The organization lobbies on specific legislation including Medicare payment stabilization and prior authorization reform bills.

Competitive Landscape

Allied organizations amplify similar messages. The American College of Gastroenterology files multiple lobbying disclosures on colonoscopy coverage and Medicare issues. The Crohn’s & Colitis Foundation focuses on IBD research funding. The Digestive Disease National Coalition advocates for NIH appropriations.

Between The Lines

Rep. Mark Green reintroduced prior authorization reform legislation citing colonoscopy delays. Senators Marshall and Warner pushed Medicare Advantage reforms. Rep. Greg Murphy introduced bills addressing Part B drug reimbursement for Crohn’s treatments. Multiple lawmakers condemned NIH grant terminations threatening research.

The Bottom Line

AGA’s in-house lobbying model provides cost-effective advocacy on complex medical issues. With bipartisan momentum on prior authorization reform and Medicare payment concerns, the organization is positioned for potential policy wins. However, research funding threats and reimbursement pressures require sustained advocacy investment.

Spot something wrong? Report an issue with this article